Product Images Fluticasone Propionate And Salmeterol Diskus

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 16 images provide visual information about the product associated with Fluticasone Propionate And Salmeterol Diskus NDC 53002-1568 by Rpk Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Fluticasone propionate chemical structure - fp sal spl graphic 01

Fluticasone propionate chemical structure - fp sal spl graphic 01

Salmeterol xinafoate chemical structure - fp sal spl graphic 02

Salmeterol xinafoate chemical structure - fp sal spl graphic 02

Figure 1. Mean Percent Change from Baseline in FEV1 in Subjects with Asthma Previously Treated with Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 03

Figure 1. Mean Percent Change from Baseline in FEV1 in Subjects with Asthma Previously Treated with Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 03

Figure 2. Percent Change in Serial 12-Hour FEV1 in Subjects with Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 04

Figure 2. Percent Change in Serial 12-Hour FEV1 in Subjects with Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 04

Figure 3. Percent Change in Serial 12-Hour FEV1 in Subjects with Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 05

Figure 3. Percent Change in Serial 12-Hour FEV1 in Subjects with Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 05

Figure 4. Predose FEV1: Mean Percent Change from Baseline in Subjects with Chronic Obstructive Pulmonary Disease - fp sal spl graphic 06

Figure 4. Predose FEV1: Mean Percent Change from Baseline in Subjects with Chronic Obstructive Pulmonary Disease - fp sal spl graphic 06

Figure 5. Two-Hour Postdose FEV1: Mean Percent Changes from Baseline over Time in Subjects with Chronic Obstructive Pulmonary Disease - fp sal spl graphic 07

Figure 5. Two-Hour Postdose FEV1: Mean Percent Changes from Baseline over Time in Subjects with Chronic Obstructive Pulmonary Disease - fp sal spl graphic 07

Figure A - fp sal spl graphic 08

Figure A - fp sal spl graphic 08

Figure B - fp sal spl graphic 09

Figure B - fp sal spl graphic 09

Figure C - fp sal spl graphic 10

Figure C - fp sal spl graphic 10

Figure D - fp sal spl graphic 11

Figure D - fp sal spl graphic 11

Figure E - fp sal spl graphic 12

Figure E - fp sal spl graphic 12

Figure F - fp sal spl graphic 13

Figure F - fp sal spl graphic 13

Figure G - fp sal spl graphic 14

Figure G - fp sal spl graphic 14

Figure H - fp sal spl graphic 15

Figure H - fp sal spl graphic 15

Label Image - lbl530021568

Label Image - lbl530021568